,12 Along with other VEGF-targeting drugs, ranibizumab effectively manages wet AMD, diabetic retinopathy, and diabetic macular edema (among other retinal vascular diseases), slowing disease progression.11 Here, VEGFA is linked to wet macular degeneration.